POS1336 DIAGNOSTIC VALUE OF VEIN WALL THICKNESS MEASUREMENT FOR PATIENTS WITH SUSPECTED BEHÇET SYNDROME

Le résumé fourni par la source

Background: Increased venous wall thickness is well recognized in Behçet syndrome (BS). Venous wall thickness measurement with ultrasonography was proposed as a tool that can differentiate BS from other diseases. However, studies have shown conflicting results on its diagnostic utility. A good method for testing this would be measuring common femoral vein wall thickness (CFVWT) with Doppler ultrasonography among patients with suspected BS who are referred for screening. Objectives: To evaluate whether measuring CFVWT using Doppler ultrasonography in patients with suspected BS referred for screening can differentiate BS from non-BS etiologies. Methods: All individuals referred to our clinic for BS screening between May 2023 and December 2023 underwent venous Doppler ultrasonography of lower extremities by 2 independent radiologists blinded to the patients' clinical and laboratory findings. Thirty vascular BS patients with lower extremity deep vein thrombosis (LEDVT) who were already being followed in our clinic and 36 healthy subjects were recruited as controls. Results: Among the 84 referred individuals, 45 were diagnosed with BS and 39 with other conditions (non-BS). Non-BS etiologies consisted of various inflammatory conditions such as spondyloarthritis, uveitis, inflammatory bowel disease, recurrent aphthous stomatitis, connective tissue diseases, systemic autoinflammatory diseases, and chronic thromboembolic pulmonary hypertension. Demographics and clinical characteristics of the patients and controls are provided in the Table 1. Healthy controls were younger, less frequently smoker, and had a lower body mass index compared to other groups. Among the 84 patients who were referred for screening, LEDVT was present in 5/45 BS patients and in 2/39 non-BS patients. The highest median (Q1-Q3) CFVWT was observed in patients with vascular BS [0.76 mm (0.63-0.87) for right and 0.71 mm (0.62-0.86) for left], followed by those with BS [0.59 mm (0.53-0.69) for right and 0.60 mm (0.50-0.68) for left], non-BS [0.57 (0.50-0.66) for right and 0.57 mm (0.49-0.67) for left], and healthy subjects [0.49 (0.47-0.53) for right and 0.48 mm (0.43-0.50) for left]. Both right and left median CFVWT was significantly higher among vascular BS (p<0.001 for all) and lower among healthy controls (p<0.001 for all), whereas there was no significant difference between patients with and without BS who were referred for screening (Figure 1). Conclusion: CFVWT was higher in both BS and non-BS patients compared to healthy subjects. However, its measurement did not help the differential diagnosis of new patients with BS from non-BS patients sent to our clinic with a suspicion of BS. The significantly higher CFVWT in vascular BS patients compared to BS patients without LEDVT raises the question of whether this is related to vascular remodeling or whether the thickening is associated with inflammation of the vein wall. REFERENCES: NIL . Table 1Demographics, clinical characteristics, and common femoral vein wall thickness of the patients and the controlsBS(n=45)Non-BS(n=39)Vascular BS(n=30)Healthy controls(n=36)Male, n (%)19 (42)22 (56)27 (90)17 (47.2)Mean (SD) age, yrs38.1±11.138.9±10.942.3 ± 10.931.4 ± 7.9Mean (SD) BMI26.0 ± 5.126.4 ± 5.426.1 ± 3.824.4 ± 2.9Smoking history, n (%)26 (57.8)20 (51.3)22 (73.3)7 (19.4)Oral ulcer, n (%)45 (100)23 (59)30 (100)N/AGenital ulcer, n (%)33 (73.3)016 (53.3)N/APPL, n (%)37 (82.2)16 (431)20 (66.7)N/AErythema nodosum, n (%)17 (37.8)011 (36.7)N/AArthritis/arthralgia, n (%)12 (26.7)5 (12.8)3 (10)N/AUveitis, n (%)19 (42.2)09 (30)N/ALower extremity DVT, n (%)5 (11.1)2 (5.1)30 (100)N/APathergy, n (%)13/40 (32.5)2/38 (5.3)9/25 (36)N/AMedian (Q1-Q3) right CFVWT, mm0.59 (0.53-0.69)0.57 (0.50-0.66)0.76 (0.63-0.87)0.49 (0.47-0.53)Median (Q1-Q3) left CFVWT, mm0.60 (0.50-0.68)0.57 (0.49-0.67)0.71 (0.62 -0.86)0.48 (0.43 -0.50)BS: Behçet's syndrome; BMI: Body mass index; CFVWT: Common femoral vein wall thickness; DVT: Deep vein thrombosis; PPL: Papulopustular lesions; Q1-Q3: First-third quartile, SD: Standard deviation Acknowledgements: NIL . Disclosure of Interests: Ruken Alcin: None declared, Yasemin Kayadibi: None declared, Aysenur Kahveci: None declared, Sinem Nihal Esatoglu: None declared, İbrahim Adaletli: None declared, Yesim Ozguler: None declared, Melike Melikoglu: None declared, Gulen Hatemi Gulen Hatemi received research grants, speaker fees, and/or consulting fees from Abbvie, Amgen, Boehringer Ingelheim, Deva Pharmaceuticals, Novartis, Pfizer, Soligenix, and UCB Pharma. © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.